Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

Next Previous
X
Search
Trial Profile

Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
  • Indications Post-transplant lymphoproliferative disorder
  • Focus Therapeutic Use
  • Acronyms TIDaL

    • Most Recent Events

    • 14 Dec 2021 Results (n=39; Between January 2017 and March 2020) assessing efficacy and safety of ibrutinib and rituximab and IR-CHOP for de-novo post-transplant lymphoproliferative disorder, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 15 May 2021 Status changed from active, no longer recruiting to completed.
    • 15 Dec 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top